Joseph Pape

Array ( [id] => 16297767 [patent_doc_number] => 20200283490 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => ACTIVATABLE INTERLEUKIN-2 POLYPEPTIDES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/880606 [patent_app_country] => US [patent_app_date] => 2020-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33928 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16880606 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18028949 [patent_doc_number] => 11512122 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-29 [patent_title] => IL-7-FC-fusion proteins [patent_app_type] => utility [patent_app_number] => 16/875878 [patent_app_country] => US [patent_app_date] => 2020-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 63 [patent_figures_cnt] => 63 [patent_no_of_words] => 25531 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16875878 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16711908 [patent_doc_number] => 20210079055 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => SUPERAGONISTS, PARTIAL AGONISTS AND ANTAGONISTS OF INTERLEUKIN-2 [patent_app_type] => utility [patent_app_number] => 15/930057 [patent_app_country] => US [patent_app_date] => 2020-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27317 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15930057 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17733330 [patent_doc_number] => 20220218789 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => Nogapendekin Alfa-Inbakicept For Immune Stimulant Therapies And Treatment Of Viral Infections [patent_app_type] => utility [patent_app_number] => 17/594940 [patent_app_country] => US [patent_app_date] => 2020-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9284 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17594940 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16421930 [patent_doc_number] => 20200347128 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => MODULATING THE EFFECTS OF GAMMA-C-CYTOKINE SIGNALING FOR THE TREATMENT OF ALOPECIA AND ALOPECIA ASSOCIATED DISORDERS [patent_app_type] => utility [patent_app_number] => 16/863914 [patent_app_country] => US [patent_app_date] => 2020-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27446 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16863914 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16328427 [patent_doc_number] => 20200299393 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-24 [patent_title] => METHODS FOR TREATING ALLERGY AND ENHANCING ALLERGEN-SPECIFIC IMMUNOTHERAPY BY ADMINISTERING AN IL-4R INHIBITOR [patent_app_type] => utility [patent_app_number] => 16/858488 [patent_app_country] => US [patent_app_date] => 2020-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9266 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16858488 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18354024 [patent_doc_number] => 11642409 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-09 [patent_title] => Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof [patent_app_type] => utility [patent_app_number] => 16/857999 [patent_app_country] => US [patent_app_date] => 2020-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 78 [patent_no_of_words] => 78408 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16857999 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16727849 [patent_doc_number] => 20210094996 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-01 [patent_title] => Targeted Immunotolerance [patent_app_type] => utility [patent_app_number] => 16/857340 [patent_app_country] => US [patent_app_date] => 2020-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57427 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16857340 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17720431 [patent_doc_number] => 20220213151 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => COMPOSITIONS AND METHODS FOR TREATMENT OF DISTENTABLE TISSUES [patent_app_type] => utility [patent_app_number] => 17/602193 [patent_app_country] => US [patent_app_date] => 2020-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7142 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17602193 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16598121 [patent_doc_number] => 20210024652 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => Compositions and Methods to Regulate Renalase in the Treatment of Cancer [patent_app_type] => utility [patent_app_number] => 16/847964 [patent_app_country] => US [patent_app_date] => 2020-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38974 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16847964 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16628729 [patent_doc_number] => 20210047382 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-18 [patent_title] => MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES [patent_app_type] => utility [patent_app_number] => 16/841815 [patent_app_country] => US [patent_app_date] => 2020-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14528 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16841815 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20270749 [patent_doc_number] => 12440513 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-14 [patent_title] => Methods for improving cognitive function [patent_app_type] => utility [patent_app_number] => 17/441613 [patent_app_country] => US [patent_app_date] => 2020-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 113 [patent_no_of_words] => 22042 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17441613 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17453039 [patent_doc_number] => 11267884 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-08 [patent_title] => Antibody to human IL-1 beta [patent_app_type] => utility [patent_app_number] => 16/822952 [patent_app_country] => US [patent_app_date] => 2020-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 7 [patent_no_of_words] => 21681 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16822952 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16090465 [patent_doc_number] => 20200199219 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => BIOPHARMACEUTICAL COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 16/806071 [patent_app_country] => US [patent_app_date] => 2020-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40981 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16806071 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17556103 [patent_doc_number] => 11312779 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-26 [patent_title] => Methods of treating prurigo nodularis using anti-IL-31RA antibody compositions [patent_app_type] => utility [patent_app_number] => 16/804475 [patent_app_country] => US [patent_app_date] => 2020-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19343 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16804475 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16283768 [patent_doc_number] => 20200277370 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => TREATMENT OF HIDRADENITIS SUPPURATIVA [patent_app_type] => utility [patent_app_number] => 16/803177 [patent_app_country] => US [patent_app_date] => 2020-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10326 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16803177 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17546748 [patent_doc_number] => 20220118089 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND AUTOIMMUNE CONDITIONS WITH ECM-AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS [patent_app_type] => utility [patent_app_number] => 17/310802 [patent_app_country] => US [patent_app_date] => 2020-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46020 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -49 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17310802 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16268853 [patent_doc_number] => 20200270340 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => TREATMENT OF KIDNEY INJURY [patent_app_type] => utility [patent_app_number] => 16/798101 [patent_app_country] => US [patent_app_date] => 2020-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36081 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16798101 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17073770 [patent_doc_number] => 11110149 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-07 [patent_title] => Method for predicting and monitoring the efficacy of low-dose IL-2 and hydroxychloroquine therapy in autoimmune diseases and its long-term use in autoimmune-related conditions [patent_app_type] => utility [patent_app_number] => 16/794585 [patent_app_country] => US [patent_app_date] => 2020-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 53 [patent_no_of_words] => 7735 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16794585 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20437488 [patent_doc_number] => 12508309 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-30 [patent_title] => Recombinant viral vector, immunogenic composition comprising same, and uses [patent_app_type] => utility [patent_app_number] => 17/800637 [patent_app_country] => US [patent_app_date] => 2020-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 4 [patent_no_of_words] => 0 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17800637 [rel_patent_id] =>[rel_patent_doc_number] =>)